TRN 226
Alternative Names: TRN-226Latest Information Update: 28 Jul 2024
At a glance
- Originator Tris Pharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA (PO)
- 07 Jun 2021 TRN 226 is available for licensing as of 07 Jun 2021. https://www.trispharma.com/connect/partnership/
- 07 Jun 2021 Tris Pharma has patent protection for LiquiXR® technology (Tris Pharma pipeline, June 2021)